医学临床研究
   Jul. 13, 2025    Home  |  About Journal  |  Editorial Board  |  Instruction  |  Subscribe  |  Advertisement  |  Messages Board  |  Contact Us  |  中文
JOURNAL OF CLINICAL RESEARCH  2022, Vol. 39 Issue (7): 1002-1005    DOI: 10.3969/j.issn.1671-7171.2022.07.012
OriginalArticles Current Issue | Archive | Adv Search |
Efficacy and Safety of Arotinib Combined with Ektinib in Patients with Stage ⅢB/ Ⅳ EGFR Gene Mutant Non-small Cell Lung Cancer
JIANG Zhou, CHEN Jian-hua
Department of Thoracic Medicine,Affiliated Cancer Hospital of Xiangya School of Medicine,Central South University,Hunan Cancer Hospital,Changsha Hunan 410031
Download: PDF (1468 KB)   HTML (1 KB) 
Export: BibTeX | EndNote (RIS)      
Abstract  【Objective】 To investigate the efficacy and safety of Arotinib combined with Ektinib in the treatment of non-small cell lung cancer (NSCLC) patients with stage ⅢB/Ⅳ human epidermal growth factor receptor (EGFR) gene mutations. 【Methods】A total of 27 patients with stage ⅢB/Ⅳ EGFR mutant NSCLC initially treated in our hospital from March 2019 to March 2021 were randomly divided into the observation group (treated with Arotinib combined with Ektinib) and the control group (treated with Ektinib). The efficacy, progression free survival (PFS), objective response rate (ORR) and disease control rate (DCR) of the two groups were compared. 【Results】Up to March 2022, the median PFS in the observation group was 15.50 months, significantly longer than 10.00 months in the control group, and the difference was statistically significant. According to different mutation types, they were divided into 19 exon deletion L858R point mutation group and 21 exon deletion L858R point mutation group. The median PFS of patients with 19 exon deletion L858R point mutation group in the observation group was 16.00 months, significantly higher than that of patients with 19 exon deletion L858R point mutation group in the control group for 11.75 months, and the difference was statistically significant (P<0.05); The median PFS of patients with exon 21 deletion L858R point mutation in the observation group was 14.00 months, compared with 8.50 months in patients with exon 21 deletion L858R point mutation in the control group, the difference was not statistically significant (P>0.05); After 6 weeks of treatment, the ORR and DCR of the observation group were 75.00% (9/12) and 91.67% (11/12), respectively, compared with 53.33% (8/15) and 80.00% (12/15) of the control group, the difference was not statistically significant (P>0.05). The proportion of hypertension and gingival bleeding in the observation group was higher, in which 2 cases of hypertension and transaminase increased by 3 levels, and all of them decreased to 1 level after symptomatic treatment with drugs; The incidence of skin rash, skin pruritus and paronychia in the control group was slightly higher than that in the observation group. The incidence of skin rash, skin pruritus, paronychia and transaminase increased by 3 levels. After symptomatic treatment, they all improved and can continue to be treated. The toxic and side effects of the two groups of patients were controllable as a whole. 【Conclusion】 Arotinib combined with Ektinib can significantly improve PFS in patients with stage ⅢB/Ⅳ NSCLC, and the safety is good.
Key wordsCarcinoma, Non-Small-Cell Lung/DT      Genes, erbB-1      Mutation      Molecular Targeted Therapy      Treatment Outcome     
Received: 13 June 2022     
PACS:  R734.2  
Service
E-mail this article
Add to my bookshelf
Add to citation manager
E-mail Alert
RSS
Articles by authors
JIANG Zhou
CHEN Jian-hua
Cite this article:   
JIANG Zhou,CHEN Jian-hua. Efficacy and Safety of Arotinib Combined with Ektinib in Patients with Stage ⅢB/ Ⅳ EGFR Gene Mutant Non-small Cell Lung Cancer[J]. JOURNAL OF CLINICAL RESEARCH, 2022, 39(7): 1002-1005.
URL:  
http://journal07.magtech.org.cn/yxlcyj/EN/10.3969/j.issn.1671-7171.2022.07.012     OR     http://journal07.magtech.org.cn/yxlcyj/EN/Y2022/V39/I7/1002
Copyright © Editorial Board of JOURNAL OF CLINICAL RESEARCH
Supported by:Beijing Magtech